Team 4
Upcoming SlideShare
Loading in...5
×
 

Team 4

on

  • 405 views

 

Statistics

Views

Total Views
405
Views on SlideShare
405
Embed Views
0

Actions

Likes
0
Downloads
5
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Team 4 Team 4 Presentation Transcript

    • TEAM 4
      Hussein El shamy, Engyhelaly, Ayaat Ali, EslamEl shahat and MarwanFelafel
    • Where are we now?
      Novartis is a great company which works hard to help patients.
      The major targets of Novartis are patients’ health and patients’ trust.
      Novartis want to cover all patients who have chronic myeloid leukemia ( CML ) in Egypt.
      Novartis produces 2nd line treatment for ( CML ) which is called Pluto.
    • Executive summary
      Our aim is to be ranked the second in the market within 5 years.
      The project is prepared to invest 660,000L.E. and to gain 4,320,000l in the first year with an annual increase in the profit around 10%.
    • SWOT
      Strengths:
      • Rapid & durable response.
      • Effective & safe.
      • Former experience.
      • No cross intolerence with Mirac.
      Opportunities:
      • Former trust with the customers.
      • Limited number of competitors.
      Weaknesses:
      • Hypertensive patients.
      • Possibility of incompliance.
      Threats:
      • Patient Perception.
      - Managing response.
    • Where do we want to be?
      Mission statement
    • Strategy Objectives
      Objectives
      Mission
      Goals
    • Qualitative objectives:
      • Higher product quality
      • Recognition as a leader in the leukemia market
      • Higher levels of customer satisfaction and compliance
      • Creating strong reputation in the market.
    • Quantitative objectives:
    • Augmenting the market share by: 19%
      Increasing the number of targeted patients by 304 patients.
      Increasing sales by 5,472,000 LE
      Improving the drug ranking against competitors 2nd
      Developing a good ROI & KPI
      • Product variation
      • Pluto is an innovative product
      • Faster 6-9 months only
      • Two distribution patterns
      Our target is to make Pluto have 100% of the market share
      • We need to reach 75% of the patients
      • Then we will decrease the price by 15%.
      • Medical rep. (4 and 1 DM)
      • Sessions in conferences
      • Local congresses
    • Discussion panels Seminars organized by the company
      E-mail and Phone team
      Governmental sector
      Direct marketing i.e. Med. Rep
      Printed Fliers and Brochures
      Sessions in conferences and Sponsorship
    • How might we get there?
    • Another problem is: Dasatinib
      But our drug is:
      MoreSelective
      With LessAdverse effects
      AND it is Cheaper!
    • Strategy implementation and evaluation (financial plan)
    • Strategy implementation and evaluation (financial plan)
    • Action Plan
    • How can we ensure our arrival?
      Key Performance Indicators:
    • Thank You